Brief: Axsome Therapeutics Acquires AZD7325, A Selective GABA-A Modulator For Treatment Of Epilepsy
06/11/2025 12:29
Nov 6 (Reuters) - Axsome Therapeutics Inc AXSM.O: AXSOME THERAPEUTICS ACQUIRES SUBTYPE SELECTIVE GABA-A RECEPTOR POSITIVE ALLOSTERIC MODULATOR AZD7325 FOR THE TREATMENT OF EPILEPSY AXSOME THERAPEUTICS INC - OBTAINS EXCLUSIVE GLOBAL RIGHTS TO AZD7325 AXSOME THERAPEUTICS INC - TO BEGIN PHASE 2 TRIAL ACTIVITIES FOR AZD7325 IN 2026 Source text: ID:nGNX8Rwsfs Further company coverage: AXSM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avenue Therapeutics
See all newsBrief: Axsome Therapeutics Acquires AZD7325, A Selective GABA-A Modulator For Treatment Of Epilepsy
Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Avenue Therapeutics Annji Intends To Terminate License Agreement With Co
Brief: Avenue Therapeutics Receives Delist Letter From Nasdaq Under Nasdaq Listing Rule 5550(B)(1)
Avenue Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary